While there are certainly fewer studies focusing on circulating levels of sPD-1 than sPD-L1, six different reports involving 299 cancer patients have shown that high levels of sPD-1 prior to conventional therapy correlated with a shorter PFS or OS following treatment (Table 4). This evidence concerns the gene HOXD13 and cancer.